Skip to content
lifestyle.celebhomes.net
Home
Sample Page
Author:
Halia Therapeutics
Halia Therapeutics Appoints Gary Sabin as Executive Chairman and Adds Three Independent Directors to Board
May 19, 2026
Halia Therapeutics to Present Final Phase 2 Ofirnoflast Data in Lower-Risk MDS at EHA2026 and Announces Appointment of Han Myint, MD, FACP, as Chief Medical Officer
May 12, 2026
Halia Therapeutics Announces Positive Phase 2a Data for Ofirnoflast in Lower-Risk MDS at ASH 2025
December 8, 2025